These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35217173)

  • 21. Hesperidin Ameliorates Anxiety-Depressive-Like Behavior in 6-OHDA Model of Parkinson's Disease by Regulating Striatal Cytokine and Neurotrophic Factors Levels and Dopaminergic Innervation Loss in the Striatum of Mice.
    Antunes MS; Cattelan Souza L; Ladd FVL; Ladd AABL; Moreira AL; Bortolotto VC; Silva MRP; Araújo SM; Prigol M; Nogueira CW; Boeira SP
    Mol Neurobiol; 2020 Jul; 57(7):3027-3041. PubMed ID: 32458386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Aging on the 6-OHDA-Induced Rat Model of Parkinson's Disease.
    Barata-Antunes S; Teixeira FG; Mendes-Pinheiro B; Domingues AV; Vilaça-Faria H; Marote A; Silva D; Sousa RA; Salgado AJ
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32422916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Voluntary Physical Exercise Exerts Neuroprotective Effects and Motor Disturbance Alleviation in a Rat Model of Parkinson's Disease.
    Tsai WL; Chen HY; Huang YZ; Chen YH; Kuo CW; Chen KY; Hsieh TH
    Behav Neurol; 2019; 2019():4829572. PubMed ID: 31885725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
    Mori MA; Delattre AM; Carabelli B; Pudell C; Bortolanza M; Staziaki PV; Visentainer JV; Montanher PF; Del Bel EA; Ferraz AC
    Nutr Neurosci; 2018 Jun; 21(5):341-351. PubMed ID: 28221817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.
    Mazzocchi M; Wyatt SL; Mercatelli D; Morari M; Morales-Prieto N; Collins LM; Sullivan AM; O'Keeffe GW
    Front Cell Dev Biol; 2019; 7():191. PubMed ID: 31572723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early post-treatment with 9-cis retinoic acid reduces neurodegeneration of dopaminergic neurons in a rat model of Parkinson's disease.
    Yin LH; Shen H; Diaz-Ruiz O; Bäckman CM; Bae E; Yu SJ; Wang Y
    BMC Neurosci; 2012 Oct; 13():120. PubMed ID: 23040108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Jang H; Kim S; Lee JM; Oh YS; Park SM; Kim SR
    Neuroreport; 2017 Mar; 28(5):242-249. PubMed ID: 28178069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
    Tentillier N; Etzerodt A; Olesen MN; Rizalar FS; Jacobsen J; Bender D; Moestrup SK; Romero-Ramos M
    J Neurosci; 2016 Sep; 36(36):9375-90. PubMed ID: 27605613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway.
    Lou H; Jing X; Wei X; Shi H; Ren D; Zhang X
    Neuropharmacology; 2014 Apr; 79():380-8. PubMed ID: 24333330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rutin protects dopaminergic neurons from oxidative stress in an animal model of Parkinson's disease.
    Khan MM; Raza SS; Javed H; Ahmad A; Khan A; Islam F; Safhi MM; Islam F
    Neurotox Res; 2012 Jul; 22(1):1-15. PubMed ID: 22194158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.
    Barnum CJ; Chen X; Chung J; Chang J; Williams M; Grigoryan N; Tesi RJ; Tansey MG
    J Parkinsons Dis; 2014; 4(3):349-60. PubMed ID: 25061061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.
    Xiong C; Guan Y; Zhou X; Liu L; Zhuang MA; Zhang W; Zhang Y; Masucci MV; Bayliss G; Zhao TC; Zhuang S
    FASEB J; 2019 Jul; 33(7):8249-8262. PubMed ID: 30951378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naringin treatment induces neuroprotective effects in a mouse model of Parkinson's disease in vivo, but not enough to restore the lesioned dopaminergic system.
    Kim HD; Jeong KH; Jung UJ; Kim SR
    J Nutr Biochem; 2016 Feb; 28():140-6. PubMed ID: 26878791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C; Papazoglou A; Just L; Nikkhah G
    Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson's disease.
    Ikeda-Matsuo Y; Miyata H; Mizoguchi T; Ohama E; Naito Y; Uematsu S; Akira S; Sasaki Y; Tanabe M
    Neurobiol Dis; 2019 Apr; 124():81-92. PubMed ID: 30423474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Estrogen protects the dopaminergic neurons in substantia nigra against damage induced by 6-hydroxydopamine].
    Meng JL; Ma YY; Luo HY; Kong SZ; He YW; Dong BC; Wu SH; He M
    Sheng Li Xue Bao; 2008 Jun; 60(3):369-74. PubMed ID: 18560728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time course of dopamine neuron loss and glial response in the 6-OHDA striatal mouse model of Parkinson's disease.
    Stott SRW; Barker RA
    Eur J Neurosci; 2014 Mar; 39(6):1042-1056. PubMed ID: 24372914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.